Cantor Fitzgerald Predicts Annexon FY2026 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for Annexon in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($1.29) for the year. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07).

ANNX has been the topic of a number of other research reports. HC Wainwright reduced their target price on Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Needham & Company LLC cut their price objective on Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th.

Annexon Trading Up 7.5%

Shares of ANNX opened at $2.71 on Wednesday. Annexon has a 1 year low of $1.29 and a 1 year high of $7.85. The stock has a market cap of $297.32 million, a P/E ratio of -2.58 and a beta of 1.26. The stock’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $3.13.

Hedge Funds Weigh In On Annexon

Institutional investors have recently modified their holdings of the business. Alpine Global Management LLC bought a new position in shares of Annexon during the 1st quarter valued at about $49,000. Forefront Analytics LLC lifted its holdings in shares of Annexon by 74.0% during the 1st quarter. Forefront Analytics LLC now owns 28,591 shares of the company’s stock valued at $55,000 after purchasing an additional 12,158 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Annexon during the 4th quarter valued at about $59,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Annexon by 164.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company’s stock valued at $66,000 after purchasing an additional 21,143 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Annexon by 19.9% during the 1st quarter. Hsbc Holdings PLC now owns 36,935 shares of the company’s stock valued at $73,000 after purchasing an additional 6,136 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.